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genes (DEGs) were validated by real-time polymerase chain reaction
(PCR) and immunohistochemical staining in IgG4-RD (n¼ 18), CS
(n¼ 4), Sjo¨gren syndrome (n¼ 11), and controls (n¼ 10).
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Abstract: IgG4-related disease (IgG4-RD) is a novel systemic disease
entity characterized by elevated serum IgG4 and tissue infiltration of
IgG4-positive plasma cells accompanied by severe fibrosis. Although
recent studies demonstrated that innate immune cells including mono-
cytes and macrophages might promote local fibrosis and IgG4 pro-
duction, the pathological mechanism remains unclear. In this study,
we sought to identify the disease-associated genes, especially innate
immune molecules.
Gene expression was analyzed by DNA microarray in submandib-
ular glands (SMGs) from patients with IgG4-RD (n¼ 5), chronic
sialoadenitis (CS) (n¼ 3), and controls (n¼ 3). Differentially expressedDDS, PhD, Yasuh , PhD,
a, MD, PhD, and Seiji Nakamura, DDS, PhD
Gene expression patterns in the 3 groups were quite different from
each other by the pvclust method and principal components analysis.
In IgG4-RD, 1028 upregulated genes and 692 downregulated genes
were identified as DEGs (P< 0.05). Gene Ontology (GO) term analysis
indicated that the upregulated DEGs in IgG4-RD encoded proteins
involved in T/B cell activation and chemotaxis. PCR validated signifi-
cantly higher expression of macrophage receptor with collagenous
structure (MARCO), a pattern-recognition receptor, in IgG4-RD com-
pared with the other groups (P< 0.01). Immunohistochemical analysis
confirmed that the expression pattern of MARCO was similar to that of
the M2 macrophage marker CD163.
MARCO was identified as a disease-associated molecule in IgG4-
RD by DNA microarray. Moreover, M2 macrophages might contribute
to the initiation of IgG4-RD via MARCO.
(Medicine 95(7):e2853)
Abbreviations: CCL18 = CC chemokine ligand 18, CHIT 1 =
chitinase 1, CS = chronic sialoadenitis, DAVID = Database for
Annotation, Visualization and Integrated Discovery, DC = dendritic
cell, DEG = differentially expressed gene, dNTP =
deoxyribonucleotide triphosphate, DTT = dithiothreitol, GC =
germinal center, GO = Gene Ontology, HE = hematoxylin and
eosin, IgG4-DS = IgG4-related dacryoadenitis and sialoadenitis,
IgG4-RD = IgG4-related disease, IHC = immunohistochemical
staining, IL = interleukin, LDL = low density lipoprotein, limma =
Linear Models for Microarray Analysis, LPS = lipopolysaccharide,
LSG = labial salivary gland, MARCO = macrophage receptor with
collagenous structure, OSCC = oral squamous cell carcinoma, PC =
principal component, PCA = principal components analysis, PCR =
polymerase chain reaction, SD = standard deviation, SMG =
submandibular gland, SS = Sjo¨gren syndrome, Th2 = T helper type
2, TLR = toll-like receptor.
INTRODUCTION
I gG4-related disease (IgG4-RD) is a systemic disease present-ing in multiple target organs, including pancreas, salivary and
lacrimal glands, lung, thyroid, liver, kidney, aorta, prostate,
retroperitoneum, and lymph nodes.1,2 This disease is charac-
terized by elevated serum IgG4 concentration and swelling of
affected organs with marked infiltration of IgG4- positive
plasma cells, hyperplastic ectopic germinal center (GC) for-
mation and severe fibrosis. IgG4-related dacryoadenitis and
sialoadenitis (IgG4-DS), so-called Mikulic¸z disease, has beenype of Sjo¨gren syndrome (SS) based on
imilarities in glandular tissue. However,
et al3 reported that Mikulic¸z disease
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demonstrated high serum IgG4 concentration and the infiltra-
tion of IgG4-positive plasma cells in glandular tissue, and was
distinguishable from SS.
Regarding the immunological aspects of this disease, it
is well known that IgG4 is induced by T helper type 2 (Th2)
cytokines such as interleukin (IL)-4 and IL-13.4 We previously
reported that specific Th cytokines, including IL-4, IL-10,
and IL-21, contributed to IgG4 production and ectopic GC
formation in IgG4-DS.5,6 In addition, recent studies indicated
that abnormal innate immune responses enhanced Th2 immune
responses and the immunopathogenesis of IgG4-RD via toll-
like receptors (TLRs) expressed by macrophages.7 Our recent
data indicated that M2 macrophages might promote Th2 inflam-
matory responses via IL-10 and CC chemokine ligand (CCL)
18 production.8 Although macrophages might play an effective
role in IgG4 production and are involved in the initiation of
IgG4-RD, the pathogenic mechanism of IgG4-RD by innate
immune reaction remains unclear.
In this study, we thus sought to identify disease-associated
genes, especially innate immune molecules, in IgG4-RD using
DNA microarray analysis. As reasonable samples for DNA
microarray in this study, we selected submandibular glands
(SMGs) because labial salivary glands (LSGs) in IgG4-RD
show greater variability in pathology even from the same
patient and less characteristic histological findings, such as
severe fibrosis and ectopic GC formation, than SMGs.9
MATERIALS AND METHODS
Patients
For DNA microarray analysis, SMG samples were
obtained from 6 patients with IgG4-RD (4 males and 2 females;
mean age standard deviation (SD), 68.2 5.0 years), 3
patients with chronic sialoadenitis (CS) caused by sialolith
(1 male and 2 females; 51.5 21.3 years), and 3 patients with
oral squamous cell carcinoma (OSCC) as a control group
(3 males; 55.7 11.1 years) who were referred to the Depart-
ment of Oral and Maxillofacial Surgery, Kyushu University
Hospital between 2010 and 2015. The patients underwent the
following procedures: open SMG biopsies for IgG4-DS as
described by Moriyama et al9; submandibulectomy for CS;
and neck dissection for OSCC. IgG4-DS was diagnosed accord-
ing to both the ‘‘comprehensive diagnostic criteria for IgG4-
related disease’’ and ‘‘diagnostic criteria for IgG4-DS.’’10 All
patients had never been treated with corticosteroids or any other
immunosuppressants before SMG biopsy. All SMG samples
from patients with IgG4-RD showed characteristic histopatho-
logical findings including marked infiltration of IgG4-positive
plasma cells, severe fibrosis, and formation of multiple ectopic
GCs. In contrast, SMGs from OSCC patients were histologi-
cally normal and lacked clinical evidence of metastasis and
radiation therapy (see Supplementary Figure 1, http://links.lww.
com/MD/A700).
This study design was approved by the Ethics Committee
of Kyushu University, Japan, and written informed consent was
obtained from all of the patients and healthy controls before
inclusion in this study (IRB serial number: 25-287).
Total RNA Isolation
Total RNA was isolated from SMGs using TRIzol Reagent
Ohta et al(Invitrogen Corp., Life Technologies, Carlsbad, CA) and then
purified using SV Total RNA Isolation and RNeasy system
(Promega Corp., Madison, WI) according to the manufacturer’s
2 | www.md-journal.cominstructions. RNA samples were quantified using a NanoDrop
ND-1000 spectrophotometer (Thermo Fisher Scientific, Inc.,
Wilmington, DE) and the quality of the RNA was confirmed
with an Experion automated electrophoresis station (Bio-Rad
Laboratories, Inc., Hercules, CA).
Gene Expression Microarrays
According to manufacturers’ instructions, the complemen-
tary RNA was amplified and labeled by Low Input Quick Amp
Labeling Kit (Agilent Technologies, Santa Clara, CA), and
hybridized to SurePrint G3 Human Gene Expression Micro-
arrays 8 60K v2 (Agilent Technologies) (DNA chip including
60,000 genes). All hybridized microarray slides were scanned
using an Agilent scanner. Relative hybridization intensities and
background hybridization values were calculated using Agilent
Feature Extraction Software (ver. 9.5.1.1).
Data Analysis and Filter Criteria
The raw signal intensities of all specimens were log2-
transformed and normalized by the quantile algorithm with
‘‘preprocessCore’’ library package11 on Bioconductor soft-
ware.12 We selected the probes that called ‘‘Present’’ flag in
at least one sample and used them to extract differentially
expressed genes (DEGs), and then applied Linear Models for
Microarray Analysis (limma) package of Bioconductor soft-
ware, and obtained DEGs. To identify up- and downregulated
genes, we calculated intensity based P values and ratios from
the quantile-normalized signal levels of each probe and com-
pared IgG4-RD and CS patients. Then, we established criteria
for regulated genes: upregulated genes, ratio4.0-fold and
P<0.05; downregulated genes, ratio0.25 and P<0.05. The
hierarchical clustering by the pvclust method13 and principal
components analysis (PCA) were applied to the DEGs from
comparison with IgG4-RD and CS. To determine significantly
over-represented Gene Ontology (GO) term categories and
significant enrichment of pathways (Enrichment Score>1.3),
we used GO annotation and the Web tool, the Database
for Annotation, Visualization and Integrated Discovery
(DAVID) provided by National Institute of Allergy and
Infectious Diseases (http://david.abcc.ncifcrf.gov/home.jsp).14,15
The TreeMap was generated by REVIGO16 to visualize signifi-
cant (P< 0.01) GO terms that were obtained from the Functional
Annotation Chart of Biological Process terms (BP_FAT category)
on DAVID.
Validation of the Microarray Results
Quantitative polymerase chain reaction (PCR) and
immunohistochemical staining (IHC) were performed to
validate the results of DNA microarray analysis. Total RNA
was extracted from SMG samples from 18 patients with IgG4-
RD, 11 patients with SS, 3 patients with CS, and 10 controls.
SS was diagnosed according to both the Research Committee on
SS of the Ministry of Health and Welfare of the Japanese
Government (1999)17 and the American-European Consensus
Group criteria for SS.18 Each patient showed objective
evidence of salivary gland involvement based on the presence
of subjective xerostomia and a decreased salivary flow
rate, abnormal findings on parotid sialography, and focal lym-
phocytic infiltrates in the LSGs. There was no documented
history of treatment with steroids or any other immunosuppres-
Medicine  Volume 95, Number 7, February 2016sants, infection with HIV, HTLV-1, hepatitis B virus, or hepatitis
C virus, or sarcoidosis in any of the patients. None of the patients
had evidence of malignant lymphoma at the time of the study.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
P-value of P< 0.05 was considered statistically significant.Extraction of RNA and Synthesis of
Complementary DNA (cDNA)
Total RNA was isolated from the whole SMG samples by
the acidified guanidinium-phenol-chloroform method. Total
RNA samples (1mg) were prepared and used for the synthesis
of cDNA and then RNA was incubated for 1 hour at 428C with
20 U of RNase inhibitor (Promega Corp.), 0.5mg of oligo-1218
(Pharmacia, Uppsala, Sweden), 0.5 mM of each deoxyribonu-
cleotide triphosphate (dNTP) (Pharmacia), 10 mM of dithio-
threitol (DTT), and 100 U of RNA reverse transcriptase (Life
Technologies, Gaithersburg, MD).
Quantitative Estimation of mRNA by
Real-Time PCR
The resulting cDNA was amplified using Light Cycler Fast
Start DNA Master mix SYBR Green III (Roche Diagnostics,
Mannheim, Germany) in a Light Cycler real-time PCR instru-
ment (version 3.5; Roche Diagnostics). The mRNA levels of
CCL18, chitinase 1 (CHIT1), macrophage receptor with col-
lagenous structure (MARCO), and TLR8 were analyzed. The
primer sequences used were as follows: CCL18 (187 bp),
forward 50-AGCTCTGCTGCCTCGTCTAT-30, reverse 50-CA-
GGCATTCAGCTTCAGGTC-30; CHIT1 (102 bp), forward
50-ATATGCCAGTGGGCAGTTTC-30, reverse 50-CCTGTTT-
CCAGGCTTCTGAG-30; MARCO (122 bp), forward 50-CAA-
TGTTCCAAAGCCCAAGAG-30, reverse 50-CCTGCAGATT-
CAGAACTTGGA-30; TLR8 (124 bp), forward 50-AAGCA-
CATCCCAAATGAAGC-30, reverse 50-GCAACTCGAGAC-
GAGGAAAC-30; b-actin (260 bp), forward 50-GCAAA-
Medicine  Volume 95, Number 7, February 2016GACCTGTACGCCAAC-30, reverse 50-CTAGAAGCATTT-
GCGGTGGA-30. The relative mRNA levels were calculated
after normalizing to the housekeeping gene b-actin.
Immunohistochemical Analysis
Serial 4-mm-thick sections of SMGs were cut from the
block of formalin-fixed and paraffin-embedded tissue and
stained with a conventional avidin–biotin complex technique
as previously described.5 Antibodies used included anti-CD68
(catalog #ab955; Abcam, Cambridge, MA), anti-CD163 (cat-
alog # NCL-CD163; Leica Biosystems, Nussloch GmbH,
Germany), and anti-CD123 (catalog # NCL-L-CD123; Leica
Biosystems) mouse monoclonal antibodies; anti-CD11c (cata-
log #52632; Abcam) and anti-CD21 (catalog #ab75985;
Abcam) rabbit monoclonal antibodies and a rabbit anti-
MARCO polyclonal antibody (catalog #AP9891A; ABGENT,
San Diego, CA). Tissue sections were sequentially incubated
with primary antibodies for 2.5 hours then with biotinylated
anti-mouse IgG or anti-rabbit IgG secondary antibodies (Vector
Laboratories, Burlingame, CA), avidin–biotin–horseradish
peroxidase complex (Vector Laboratories), and 3,30-diamino-
benzidine (Vector Laboratories). Mayer hematoxylin was used
for counterstaining. Photomicrographs were obtained using a
light microscope equipped with a digital camera (BZ-9000
series; Keyence, Tokyo, Japan).
Double Immunohistochemical Analysis
For double immunohistochemical analysis, the formalin-
fixed and paraffin-embedded sections of SMGs were immuno-
histochemically stained using an automated Bond Max stainer
(Leica Biosystems). The following primary antibodies were
used: anti-CD163 (catalog # NCL-CD163; Leica Biosystems)
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.DNA Microarray Analysis in IgG4-RDand anti-MARCO (catalog #AP9891A; ABGENT). Images
were taken using a Keyence BZ-9000 series microscope.
Statistical Analysis
The significance of differences between groups was deter-
mined using x2 test, Student t test, Mann–Whitney U test,
Kruskal–Wallis tests, and Spearman rank correlations. AAll statistical analyses were performed using JMP software
(V.8; SAS Institute, Cary, NC).
RESULTS
Identification of Gene Expression Patterns in
Patients With IgG4-RD, CS, and Controls
Table 1 summarizes the clinical and pathological fea-
tures of participating patients and controls analyzed by DNA
microarray. Microarray analysis of 60,000 gene expression
changes was performed to clarify the gene expression profiles
of SMG samples from patients with IgG4-RD, CS, and con-
trols. The scatterplot analysis and heat map to elucidate and
visualize the differences in gene expression between IgG4-
RD and CS patients showed statistically significantly differ-
ences (see Supplementary Figure 2, http://links.lww.com/
MD/A700). Figure 1 shows hierarchical clustering by the
pvclust method (Figure 1A) and PCA (Figure 1B) using the
quantile algorithm-normalized data. The gene expression
patterns in the 3 groups were quite different by hierarchical
clustering as well as by PCA. Although the 2 patients with CS
were located near the control cluster, the IgG4-RD group was
different from the other 2 groups by hierarchical clustering.
Furthermore, the gene expression patterns of the 3 groups
were divided into 3 different clusters by PCA. The contri-
bution of principal component (PC) 1 was 77.4%, and that of
PC3 was 5.0%.
Once we determined that gene expression patterns in
patients with IgG4-RD and CS differed from those in controls
by clustering analysis, we next compared gene expression and
identified genes differentially expressed between IgG4-RD and
CS in pairwise comparisons. A total of 1028 genes were
identified as upregulated in IgG4-RD compared with CS by
the rank products method (see Supplementary Table 1, http://
links.lww.com/MD/A700). In contrast, 692 genes were ident-
ified as downregulated in IgG4-RD compared with CS (see
Supplementary Table 2, http://links.lww.com/MD/A700).
Gene Annotation Enrichment Analysis of DEGs
by GO Annotation
Significantly enriched GO terms were found in the 1720
genes extracted as up- and downregulated DEGs in IgG4-RD
compared with CS as analyzed by the web tools DAVID. Of the
266 different categories by Gene annotation enrichment
analysis and the TreeMap, the following 16 categories were
identified as involved in IgG4-RD; immune responses, cell
cycle, regulation of leukocyte proliferation, nuclear division,
macrophage, cell–cell signaling, cell activation, cell adhesion,
DNA replication, ectoderm development, organelle localiz-
ation, microtubule-based process, di- or tri-valent inorganic
cation homeostasis, biological adhesion, cellular di- or tri-
valent inorganic cation homeostasis, mitosis (see Supple-
mentary Figure 3, http://links.lww.com/MD/A700).
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TABLE 1. Backgrounds of Patients With IgG4-Related Disease, Chronic Sialoadenitis, and Controls for DNA Microarray Analysis of
Submandibular Glands
Clinical Findings Histological Findings
Disease or Control,
Subject No./Age/Sex
Serum IgG
(mg/dL)
Serum IgG4
(mg/dL)
IgG4-Positive
Cells (/HPF)
Ratio of IgG4-Positive
Cells

(%)
IgG4-RD
1/60/M 5674 >1500 64 62.2
2/70/M 1476 335 83 69.3
3/67/M 5646 >1500 175 68.9
4/76/F 1637 191 67 80.0
5/71/M 3379 1360 90 70.5
6/65/F 1866 232 44 71.0
CS
1/80/F ND ND 0 0
2/24/M ND ND 0 0
3/40/F ND ND 0 0
Control
1/40/M ND ND 0 0
2/63/M ND ND 0 0
3/64/M ND ND 0 0
high
e ce
Ohta et al Medicine  Volume 95, Number 7, February 2016Validation of Candidate Genes by Quantitative
PCR
Several genes with GO terms including immune, inflam-
matory, or macrophage were in the top 120 upregulated DEGs
in IgG4-RD compared with CS (Supplementary Table 1, http://
links.lww.com/MD/A700). We chose 4 innate immunity-
related genes (CCL18 [rank 3], CHIT1 [rank 25], MARCO
[rank 34], and TLR8 [rank 117]) and validated these genes using
real-time PCR. b-actin was an appropriate internal control
because the mRNA expression level of b-actin was not signifi-
cantly different between IgG4-RD and CS in the DNA
IgG4-RD¼ IgG4-related disease, CS¼ chronic sialoadenitis, HPF¼
The ratio was calculated as IgG4-positive cells (%)¼ IgG4-positivmicroarray analysis.
As shown in Figure 2, the mRNA expression levels of
CHIT1 and TLR8 showed no statistically significant difference
FIGURE 1. Gene expression patterns in patients with IgG4-related dise
and principal components (PC) analysis (B) by using the quantile-no
4 | www.md-journal.combetween groups. In contrast, the mRNA expression levels of
CCL18 and MARCO in the SGs from patients with IgG4-RD
were significantly higher than those from the other groups. Our
previous reports8 already demonstrated that CCL18 secreted
preferentially by M2 macrophages promotes the development
of severe fibrosis in IgG4-DS. In this study, we therefore
focused on MARCO as a disease-related molecule.
Expression of MARCO in SMGs
The SMG samples frompatientswith IgG4-RD,CS, andSS,
and controls were immunohistochemically examined to evaluate
power field, ND¼ not determined.
lls/IgG-positive cells 100.the distribution of MARCO. Expression of MARCO could be
strongly detected around ectopic GCs only in patients with IgG4-
RD, but was rarely seen in the other groups (Figure 3).
ase, chronic sialoadenitis, and controls. Hierarchical clustering (A)
rmalized data.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. Quantitative PCR analysis for validation. Quantitative PCR analysis was performed using salivary glands from the patients with
and
rus
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SMGs From Patients With IgG4-RD
As MARCO is considered to be expressed on both macro-
phages and dendritic cells (DCs), we next examined the local-
ization of MARCO and the following markers of macrophages
and DCs: CD68 as a marker of both M1 and M2 macrophages;
CD163 as a marker of M2 macrophages; CD11c as a marker of
IgG4-RD and chronic sialoadenitis (CS), Sjo¨gren syndrome (SS),
Significant differences between groups were determined by the Kmyeloid DCs; CD123 as a marker of plasmacytoid DCs; and
CD21 as a marker of follicular DCs, in SMG from patients with
IgG4-RD.
FIGURE 3. Expression of MARCO in submandibular glands. Immun
(SMGs) from representative patients with IgG4-RD, CS, SS, and contro
Scale bars, 100mm.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.As shown in Figure 4, expression of CD11c and CD21
could be detected mainly in ectopic GCs in SG from patients
with IgG4-RD, while CD123 reactivity was diffuse and only
slightly detected. Interestingly, expression of CD68 and CD163
could be detected around ectopic GCs. The distribution of both
of these markers was very similar to that of MARCO.
As mentioned above, IgG4-RD shows predominant infil-
controls. The bar shows the mean value standard deviation.
kal–Wallis test (

P<0.05,

P<0.01). NS, not significant.tration of M2 macrophages over M1 macrophages in the local
lesions. Therefore, to clarify whether M2 macrophages
expressed MARCO, double staining with CD163 and MARCO
ohistochemical staining with MARCO in submandibular glands
ls. Counterstaining was performed with Mayer hematoxylin (blue).
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FIGURE 4. Distribution of MARCO-expressing cells in SMGs from representative patients with IgG4-RD. Each set of serial SMG sections
ma
ac
m.
Ohta et al Medicine  Volume 95, Number 7, February 2016was performed. Notably, CD163-positive cells (brown) were
colocalized with MARCO-positive cells (red) only in SMGs
from patients with IgG4-RD (Figure 5).
DISCUSSION
IgG4-RD is a new emerging disease entity that has
received much attention recently. Several studies have already
reported the clinical features and symptoms of this dis-
ease.1,19,20 Although IgG4-RD has been considered to be pre-
dominantly a Th2 immune response-mediated disease
5,21–23
recent studies indicated that the initiation of IgG4-RD might
was stained with MARCO, CD68 as a marker of both M1 and M2
marker of myeloid dendritic cells (DCs), CD123 as a marker of plasm
was performed with Mayer hematoxylin (blue). Scale bars, 100mbe caused by not only acquired immunity, but also innate
immunity.24,25 Watanabe et al7 demonstrated that abnormal
innate immune responses induced via TLR signaling in
FIGURE 5. Identification of MARCO-expressing cells in SMGs.
Double immunostaining with CD163 (brown) and MARCO
(red) in SMGs from representative patients with IgG4-RD, CS,
SS, and controls. Counterstaining was performed with Mayer
hematoxylin (blue). Scale bar, 50mm.
6 | www.md-journal.commonocytes/macrophages might enhance the immunopathogen-
esis of IgG4-RD. However, the detailed mechanism of patho-
genesis by the innate immune system remains to be completely
elucidated. Therefore, we performed gene expression micro-
array analysis to identify innate immune molecules, especially
related to macrophages, involved in the initiation of IgG4-RD.
We have previously analyzed the gene expression patterns in
LSG samples from patients with IgG4-RD and SS by DNA
microarray.26 However, SS is a unique inflammatory disease
similar to IgG4-RD, while CS is a nonspecific inflammatory
disease, suggesting that CS is suitable as positive controls for
IgG4-RD.
Microarray of SMGs demonstrated significant differences
in gene expression patterns among the patients with IgG4-RD,
CS, and controls. According to the results of Functional Anno-
tation Clustering on DAVID, we found that the terms related
with immune response, inflammatory response, and macro-
phage were enriched in IgG4-RD compared with CS. Thus,
IgG4-RD might be caused by some specific inflammatory
milieu and these results are consistent with past reports with
regard to the pathogenesis of IgG4-RD.
In this study, overexpression of CCL18 and MARCO in
SMGs from patients with IgG4-RD compared with the patients
with CS, SS, and controls was validated by real-time PCR.
CCL18 was identified previously as a chemokine with fibrotic
activity and selective chemotactic activity on peripheral blood T
lymphocytes, especially Th2 cells.
27 We have already reported
that CCL18 was associated with the development of severe
fibrosis in IgG4-RD.8 In addition, previous data, indicating that
tissue-infiltrating and circulating IgG4-positive cells in IgG4-
RD are polyclonal,28 suggest that there are many antigen
responses in local lesions. Thus, we focused on pattern recog-
nition receptor MARCO as a new candidate molecule related to
innate immunity in this study.
MARCO was identified as a pattern-recognition receptor
belonging to the scavenger receptors expressed by macro-
crophages, CD163 as a marker of M2 macrophages, CD11c as a
ytoid DCs, and CD21 as a marker of follicular DCs. Counterstainingphages,29 and is considered to play an important role in the
innate immune response by mediating ligand binding and
phagocytosis. This receptor can recognize various ligands
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
including bacterial lipopolysaccharide (LPS), acetylated low
density lipoprotein (LDL), apoptotic cells, lung pathogens,
Streptococcus species, and ozone-generated oxidized lipids,
environmental particles, and nanomaterials such as carbon
nanotube and silica.30 The expression of MARCO on alveolar
macrophages was reported to be strongly increased by exposure
to carbon nanotubes, which were similar in structure to asbes-
tos.31 Macrophages are well known as key regulators of the
immune system due to recognizing pathogen antigens, phago-
cytosing them and presenting them to lymphocytes. There are at
least 2 major subsets of macrophages; classically activated (M1)
macrophages stimulated by Th1-type responses and alterna-
tively activated (M2) macrophages stimulated by Th2-type
responses.32.M2 macrophages scavenge debris and contribute
to angiogenesis, suppression of adaptive immunity, wound
healing and fibrosis by producing IL-10 and CCL18.33 Murthy
et al34 found that alveolar macrophages from patients with
asbestos-induced pulmonary fibrosis showed high expression
levels of MARCO. These observations suggested that MARCO
promotes the polarization to a profibrotic M2 phenotype and
causes an excessive fibrotic response to lung injury.
Immunohistochemical analysis in our present study found
that MARCOwas strongly expressed around ectopic GC only in
IgG4-RD patients and was colocalized with CD163-positive
cells (M2 macrophages). Our previous data indicated that IgG4-
RD patients showed a predominant infiltration of M2 macro-
phages in multiple lesions including those of the pancreas,
pleura, prostate glands, lacrimal glands, and SGs.8 In addition,
IgG4-RD patients showed strong infiltration of DCs. Several
studies reported that increased DCs might play a pathological
role in IgG4-RD.35,36 However, additional research is required
to further elucidate the involvement of these cells in the
pathogenesis of IgG4-RD.
Considering the current results, M2 macrophages may
contribute to the initiation or maintenance of IgG4-RD via
MARCO. We thus made the following hypothesis regarding
the pathogenic process in IgG4-RD;M2macrophages recognize
certain exogenous or endogenous molecules through binding to
MARCO which promote the production of factors, including
IL-10 and CCL18, which precipitate an exaggerated fibrosis and
the pathology noted in IgG4-RD (see Supplementary Figure 4,
http://links.lww.com/MD/A700).
In conclusion, we have confirmed that MARCO is over-
expressed in M2 macrophages clustered around ectopic GCs.
However, we need to validate the mRNA expression levels of
MARCO and the other DEGs related to innate immunity in
many more patients, and perform functional assays to elucidate
the relationship between innate immunity and IgG4-RD. A
more thorough understanding of the role of innate immune
cells in IgG4-RD, especially M2macrophages, could lead to the
establishment of a mouse model of IgG4-RD and the develop-
ment of novel pharmacological strategies aimed at disrupting
the innate immune network and inhibiting the initiation or
progression of IgG4-RD.
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